The FDA pushed back its decision date on Cytokinetics heart drug, while AstraZeneca got Phase 3 trial results that could help ...

The rare disease-focused biotech company posted adjusted earnings per share of $0.03, surpassing the analyst consensus estimate of -$0.02. However, revenue of $125.25 million missed Wall Street’s ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 ...

In one of the largest licensing deals in the Australian biotech industry, Dimerix Limited (ASX: DXB) has sealed an exclusive ...

Dimerix (ASX: DXB), an Australian drug developer, has entered into an exclusive US licensing agreement with Amicus ...

Dimerix Ltd. sealed an exclusive license agreement with Amicus Therapeutics Inc. for commercialization of its phase III kidney disease candidate, DMX-200, in a deal valued at AU$940 million (US$601.22 ...

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) ...

Dimerix has entered an exclusive licensing deal with Amicus Therapeutics to commercialise its phase III drug candidate DMX-200 in the US. Dimerix enters exclusive licence deal with Amicus Therapeutics ...

Analysts are estimating that Amicus Therapeutics will report an earnings per share (EPS) of $0.08. The announcement from Amicus Therapeutics is eagerly anticipated, with investors seeking news of ...

Dimerix (ASX:DXB) has filled the US gap in its network of global partnerships, today revealing a US tie-up potentially worth ...